WONDER DRUG CLOBBERS DIABETES!

Patients with type 1 diabetes can take a single 14-day course of infusions to delay the disease's late stage

A BREAKTHROUGH drug recently approved by the FDA targets the root cause of type 1 diabetes (T1D) — and the first-of-its-kind treatment may delay the disease’s damaging late stage by two years or more!

 Teplizumab, an immunotherapy infusion, was given the green light for patients aged eight and above. It is intended for individuals who are in the early phases of the autoimmune condition, which ultimately leaves the body unable to control blood sugar levels.